Chris Spivey

What can we take away from Pfifzer's acquisition of Seagen?

Decreasing vein to vein time saves lives.

The further we pursue CGT, the more variability we need to account for in order to engineer consistency into these new products.

This new pioneering phase of mRNA is loaded with potential, but also obstacles and false dawns.

Public relations agencies dissect pharmaceutical trends: Brandwidth Solutions, Orientation Marketing and White Matter Communications

This compilation allows readers to adjust their thinking to appreciate the full impact certain select technologies will make on the industry by 2026.

Coverage of COVID-19 vaccines was surprisingly displaced by this year’s astounding oncology and iconoclastic gene therapy “cures.”

Logan Instruments discuses diffusion cell testing and what sets their company apart from other manufacturers.

Anthony Carpanzano, Director of R&D at JRS Pharma, discussed ongoing formulation challenges and trends.

In this episode of the Drug Solutions Podcast, Chris Spivey interviews executives at Shabas Solutions LLC, who ran the overseas QMM pilot project.

Overall industry growth conceals growing numbers of smaller, faster-paced, adaptable corporate structures.

mRNA may not be a train we necessarily all need to get onboard immediately, but we should know where the central train station is located, and what it connects us to.

Allison Labriola, Senior Technical Sales Representative, at JRS Pharma is interviewed by the Editorial Director of Pharmaceutical Technology Chris Spivey about how the food industry is affecting the pharmaceutical industry.

This video is an interview with Jon Brice, Vice President of Business Development at Asymchem at the AAPS Conference in Boston, Massachusetts.

Content is king in publishing, but interpretation is imperator.

One can only learn the secrets of "fight club" by attending its meetings.

How Pfizer’s external-facing research and development scientists uncover the most promising emerging therapy concepts and ideas in the pharmaceutical landscape.

Creating building blocks for good manufacturing practices is essential.

The flow of capital and scientific acuity irrigates this pharm system.

More than anything else MonkeyPox and COVID-19 have shown that we are interdependent, no matter what continent you call home.

Promising applications for targeted delivery may be cresting the horizon.

As we reach further afield in the molecular universe, we encounter new types of problems to resolve.

Lions and tigers and monkeypox, oh my!

FDA continues efforts to incentivize drug manufacturers to follow higher data integrity requirements.

In this episode of the Drug Solutions Podcast, Chris Spivey, editorial director, interviews Michael Kopcha, Sau Lee, and Cindy Buhse of FDA about not being afraid to try new approaches and how they invite fresh ideas and abundant communication.

Fresh insight is instrumental in the discussion of novel analytics.

3D cell cultures could provide key avenues to unlocking critical information.

Researchers from the Telomere-to-Telomere Consortium have discovered new properties about junk DNA that could have wide-reaching implications.

Borrowing is good, but invention is best.

In this episode of the Drug Solutions Podcast, Chris Spivey, Editorial Director talks about the economic and geopolitical benefits of controlling pharmaceutical manufacturing through reshoring, with Dr. Fernando Muzzio, distinguished professor of chemical and biochemical engineering, Rutgers University and Frederic Kahn, VP Sales, Wavelength Pharmaceuticals